Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype

Journal of Huntington's Disease

Volumn 4, Issue 1, 2015, Pages 17-36

  Wegrzynowicz, Michal ^a   Bichell, Terry Jo ^a,b   Soares, Barbara D ^c   Loth, Meredith K ^c   McGlothan, Jennifer L ^c   Alikhan, Fatima S ^c   Hua, Kegang ^d   Coughlin, Jennifer M ^d   Holt, Hunter K ^a   Jetter, Christopher S ^a   Mori, Susumu ^d   Pomper, Martin G ^d   Osmand, Alexander P ^e   Guilarte, Tomás R ^c,d   Bowman, Aaron B ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Medicine   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e UNIVERSITY OF TENNESSEE   (United States)

Author keywords

blood markers; body weight deficiency; brain atrophy; Htt aggregates; Huntingtin; Huntington's disease; inclusion bodies; juvenile HD; neurodegeneration; transgenic mouse; Translocator Protein 18 kDa (TSPO)

Indexed keywords

HUNTINGTIN; LEPTIN; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BACTERIAL ARTIFICIAL CHROMOSOME; BODY WEIGHT; BRAIN ATROPHY; CAG REPEAT; CONTROLLED STUDY; ENERGY METABOLISM; GLIOSIS; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; INVOLUNTARY MOVEMENT; LOCOMOTION; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; VOLUMETRY; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; ANIMAL BEHAVIOR; ATROPHY; BRAIN; C57BL MOUSE; DISEASE COURSE; DISEASE MODEL; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PROMOTER REGION; TRANSGENIC MOUSE; TRINUCLEOTIDE REPEAT;

ANIMALS; ATROPHY; BEHAVIOR, ANIMAL; BRAIN; CHROMOSOMES, ARTIFICIAL, BACTERIAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUNTINGTON DISEASE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; PHENOTYPE; PROMOTER REGIONS, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84930190550     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-140116     Document Type: Article

References (70)

1. Walker FO. Huntington's Disease. Seminars in neurology. 2007;27(2):143-50.
2. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot M, Mac- Farlane H, Jenkins B. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72(6):971-83.
3. Douaud G, Gaura V, Ribeiro MJ, Lethimonnier F, Maroy R, Verny C, Krystkowiak P, Damier P, Bachoud-Levi AC, Hantraye P, Remy P. Distribution of grey matter atrophy in Huntington's disease patients: A combined ROI-based and voxel-based morphometric study. Neuroimage. 2006;32(4):1562-75.
4. Boutell JM, Thomas P, Neal JW, Weston VJ, Duce J, Harper PS, Jones AL. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product: Huntingtin. Hum Mol Genet. 1999;8(9):1647-55.
5. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A. Huntington's disease: The current state of research with peripheral tissues. Exp Neurol. 2009;219(2):385-97.
6. Squitieri F, Frati L, Ciarmiello A, Lastoria S, Quarrell O, Juvenile. Huntington's disease: Does a dosage-effect pathogenic mechanism differ from the classical adult disease? Mech Ageing Dev. 2006;127(2):208-12.
7. Andresen JM, Gayan J, Djousse L, Roberts S, Brocklebank D, Cherny SS, Cardon LR, Gusella JF, MacDonald ME, Myers RH, Housman DE, Wexler NS. The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. Ann Hum Genet. 2007;71(Pt 3):295-301.
8. Ramaswamy S, McBride JL, Kordower JH. Animal models of Huntington's disease. ILAR J. 2007;48(4):356-73.
9. Crook ZR, Housman D. Huntington's disease: Can mice lead the way to treatment? Neuron. 2011;69(3):423-35.
10. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 2005;33(4):e36.
11. Yoo SY, Pennesi ME, Weeber EJ, Xu BS, Atkinson R, Chen SM, Armstrong DL, Wu SM, Sweatt JD, Zoghbi HY. SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron. 2003;37(3):383-401.
12. Wegrzynowicz M, Holt HK, Friedman DB, Bowman AB. Changes in the striatal proteome of YAC128Q mice exhibit gene-environment interactions between mutant huntingtin and manganese. Journal of Proteome Research. 2012;11(2): 1118-32.
13. Kreutz C, Bartolome Rodriguez MM, Maiwald T, Seidl M, Blum HE, Mohr L, Timmer. J. An error model for protein quantification. Bioinformatics. 2007;23(20):2747-53.
14. Golde WT, Gollobin P, Rodriguez LL. A rapid: Simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim (NY). 2005;34(9):39-43.
15. GuX, Greiner ER, Mishra R,Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM,Wetzel R, YangXW. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis inHDmice. Neuron. 2009;64(6):828-40.
16. Aggarwal M, Zhang J, Miller MI, Sidman RL, Mori S. Magnetic resonance imaging and micro-computed tomography combined atlas of developing and adult mouse brains for stereotaxic surgery. Neuroscience. 2009;162(4):1339-50.
17. Miller MI, Trouve A, Younes L. On the metrics and eulerlagrange equations of computational anatomy. Annu Rev Biomed Eng. 2002;4:375-405.
18. van der Burg JM, Bjorkqvist M, Brundin P. Beyond the brain: Widespread pathology in Huntington's disease. Lancet Neurol. 2009;8(8):765-74.
19. McFadyen MP, Kusek G, Bolivar VJ, Flaherty L. Differences among eight inbred strains of mice in motor ability and motor learning on a rotorod. Genes, brain, and behavior. 2003;2(4):214-9.
20. Gafni J, Papanikolaou T, Degiacomo F, Holcomb J, Chen S, Menalled L,KudwaA, Fitzpatrick J, Miller S, Ramboz S,Tuunanen PI, Lehtimaki KK,YangXW, Park L,Kwak S,Howland D, Park H, Ellerby LM. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. The Journal of neuroscience: The official journal of the Society for Neuroscience. 2012;32(22): 7454-65.
21. Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A, Feingold J, Rabier D, Durr A. Early energy deficit in Huntington disease: Identification of a plasma biomarker traceable during disease progression. PLoS One. 2007;2(7):e647.
22. Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, Moller T, Tabrizi SJ. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med. 2008;205(8):1869-77.
23. Popovic V, Svetel M, Djurovic M, Petrovic S, Doknic M, Pekic S, Miljic D, Milic N, Glodic J, Dieguez C, Casanueva FF, Kostic V. Circulating and cerebrospinal fluid ghrelin and leptin: Potential role in altered body weight in Huntington's disease. Eur J Endocrinol. 2004;151(4):451-5.
24. Bozic CR, Gerard NP, von Uexkull-Guldenband C, Kolakowski LF Jr, Conklyn MJ, Breslow R, Showell HJ, Gerard C. The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. J Biol Chem. 1994;269(47):29355-8.
25. Henry BA, Clarke IJ. Adipose tissue hormones and the regulation of food intake. J Neuroendocrinol. 2008;20(6):842-9.
26. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985;44(6): 559-77.
27. Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett. 1991;133(2):257-61.
28. Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, Pierson RK, Mills J, Langbehn DR, Paulsen JS. Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis. 2010;40(3):544-54.
29. Chen MK, Guilarte TR. Translocator protein 18 kDa (TSPO): Molecular sensor of brain injury and repair. Pharmacol Ther. 2008;118(1):1-17.
30. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003;12(13): 1555-67.
31. Vonsattel JP, Keller C, Cortes Ramirez EP. Huntington's disease - neuropathology. Handb Clin Neurol. 2011;100:83-100.
32. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3): 493-506.
33. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR. A YAC mouse model for Huntington's disease with full-length mutant huntingtin: Cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999;23(1):181-92.
34. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. The Journal of neuroscience: The official journal of the Society for Neuroscience. 2008;28(24):6182-95.
35. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet. 1999;8(3):397-407.
36. Wheeler VC, AuerbachW, White JK, Srinidhi J, Auerbach A, Ryan A, DuyaoMP, VrbanacV,Weaver M, Gusella JF, Joyner AL, MacDonald ME. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum Mol Genet. 1999;8(1):115-22.
37. Shelbourne PF, Killeen N, Hevner RF, Johnston HM, Tecott L, Lewandoski M, Ennis M, Ramirez L, Li Z, Iannicola C, Littman DR, Myers RM.AHuntington's disease CAGexpansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet. 1999; 8(5):763-74.
38. Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. The Journal of neuroscience: The official journal of the Society for Neuroscience. 2003;23(6):2193-202.
39. Heng MY, Duong DK, Albin RL, Tallaksen-Greene SJ, Hunter JM, Lesort MJ, Osmand A, Paulson HL, Detloff PJ. Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet. 2010;19(19):3702-20.
40. Roos RA. Huntington's disease: A clinical review. Orphanet J Rare Dis. 2010;5(1):40.
41. Albin RL, Reiner A, Anderson KD, Penney JB, Young AB. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol. 1990;27(4):357-65.
42. Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, Hodges JR, Rosser AE, Wood NW, Brooks DJ. Huntington's disease progression. PET and clinical observations. Brain. 1999;122 (Pt 12):2353-63.
43. Lawrence AD,Weeks RA, Brooks DJ, Andrews TC,Watkins LH, Harding AE, Robbins TW, Sahakian BJ. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain. 1998;121 (Pt 7): 1343-55.
44. Weeks RA, Piccini P, Harding AE, Brooks DJ. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol. 1996;40(1):49-54.
45. Louis ED, Anderson KE, Moskowitz C, Thorne DZ, Marder K. Dystonia-predominant adult-onset Huntington disease: Association between motor phenotype and age of onset in adults. Arch Neurol. 2000;57(9):1326-30.
46. Gonzalez-Alegre P, Afifi AK. Clinical characteristics of childhood-onset (juvenile) Huntington disease: Report of 12 patients and review of the literature. J Child Neurol. 2006; 21(3):223-9.
47. Walker FO. Huntington's disease. Lancet. 2007;369(9557): 218-28.
48. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol. 1999;46(6):842-9.
49. Romero E, Cha GH, Verstreken P, Ly CV, Hughes RE, Bellen HJ, Botas J. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron. 2008;57(1): 27-40.
50. Cummings DM, Alaghband Y, Hickey MA, Joshi PR, Hong SC, Zhu C, Ando TK, Andre VM, Cepeda C, Watson JB, Levine MS. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease. Journal of neurophysiology. 2012; 107(2):677-91.
51. Sanberg PR, Fibiger HC, Mark RF. Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med J Aust. 1981;1(8):407-9.
52. Stoy N, McKay E. Weight loss in Huntington's disease. Ann Neurol. 2000;48(1):130-1.
53. Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet. 2010;19(8):1528-38.
54. Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR. Body weight is modulated by levels of full-length huntingtin. Hum Mol Genet. 2006;15(9): 1513-23.
55. Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, Deng Y, Butland S, Zhang W, Cheng SH, Shihabuddin LS, Hayden MR. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum Mol Genet. 2012;21(10):2219-32.
56. Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson- Johnson J, Keating N, Ruiz M, Mushlin R, Alosio W, McConnell K, Connor D, Murphy C, Oakeshott S, Kwan M, Beltran J, Ghavami A, Brunner D, Park LC, Ramboz S, Howland D. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS One. 2012;7(12):e49838.
57. Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J, Graham RK, Leavitt BR, Hayden MR. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis. 2007;26(1):189-200.
58. Li MD. Leptin and beyond: An odyssey to the central control of body weight. Yale J Biol Med. 2011;84(1):1-7.
59. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: A review. Obesity reviews: An official journal of the International Association for the Study of Obesity. 2007;8(1):21-34.
60. Aziz NA, Pijl H, Frolich M, van der Graaf AW, Roelfsema F, Roos RA. Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients. Clin Endocrinol (Oxf). 2010;73(2):206-11.
61. Gabery S, Murphy K, Schultz K, Loy CT, McCusker E, Kirik D, Halliday G, Petersen A. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol. 2010;120(6):777-88.
62. Petersen A, Gil J, Maat-Schieman ML, Bjorkqvist M, Tanila H, Araujo IM, Smith R, Popovic N, Wierup N, Norlen P, Li JY, Roos RA, Sundler F, Mulder H, Brundin P. Orexin loss in Huntington's disease. Hum Mol Genet. 2005;14(1): 39-47.
63. Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P. Hypothalamic involvement in Huntington's disease: An in vivo PET study. Brain. 2008;131(Pt 11):2860-9.
64. Sipione S, Cattaneo E, Modeling. Huntington's disease in cells: Flies, and mice. Mol Neurobiol. 2001;23(1):21-51.
65. Di Paola M, Luders E, Cherubini A, Sanchez-Castaneda C, Thompson PM, Toga AW, Caltagirone C, Orobello S, Elifani F, Squitieri F, Sabatini U. Multimodal. MRI Analysis of the Corpus Callosum Reveals White Matter Differences in Presymptomatic and Early Huntington's Disease. Cereb Cortex. 2012.
66. Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, Juhl A, Pierson RK, Mills J, Langbehn D, Nance M. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010;82 (3-4): 201-7.
67. Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology. 2003;60(10):1615-20.
68. Messmer K, Reynolds GP. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. Neurosci Lett. 1998;241(1):53-6.
69. Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, Brooks DJ, Piccini P. Microglial activation correlates with severity in Huntington disease:Aclinical and PET study. Neurology. 2006;66(11):1638-43.
70. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain. 2007;130(Pt 7): 1759-66.